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Analyzing networks of phenotypes in complex
diseases: methodology and applications in
COPD
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and Edwin K Silverman1,2,3
Abstract
Background: The investigation of complex disease heterogeneity has been challenging. Here, we introduce a
network-based approach, using partial correlations, that analyzes the relationships among multiple disease-related
phenotypes.
Results: We applied this method to two large, well-characterized studies of chronic obstructive pulmonary disease
(COPD). We also examined the associations between these COPD phenotypic networks and other factors, including
case-control status, disease severity, and genetic variants. Using these phenotypic networks, we have detected novel
relationships between phenotypes that would not have been observed using traditional epidemiological approaches.
Conclusion: Phenotypic network analysis of complex diseases could provide novel insights into disease
susceptibility, disease severity, and genetic mechanisms.
Keywords: Network medicine, Phenotypic networks, COPD, Genetic association analysis
Background
Complex diseases like diabetes, stroke, many types of can-
cer, and chronic obstructive pulmonary disease (COPD)
are likely heterogeneous syndromes composed of multi-
ple disease subtypes that manifest a similar pathological
or physiological outcome. These subtypes may have dif-
ferent genetic determinants. In order to understand this
heterogeneity, a variety of clinical, physiological, imaging,
pathological, and biochemical disease-related phenotypes
have been analyzed [1]. In standard clinical epidemio-
logical approaches, univariate and multivariate regres-
sion analyses are performed to determine significant and
independent predictors of disease development. However,
the available disease-related phenotypes may be crude
assessments of disease pathophysiology; any analyses that
are performed may be confounded by grouping multiple
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subtypestogether.Thechallengeweface,inpart,isdecon-
voluting these disease-related phenotypes and defining
their relationships to one another and to specific genetic
determinants.
Network analysis has the potential to provide a holis-
tic approach to the understanding of disease complexity,
rather than focusing on individual components of disease
[2]. Network approaches can capture emergent properties
that are not apparent when network components are ana-
lyzed in a pair-wise manner. However, network medicine
approaches to complex diseases have largely focused on
relating a disease to the underlying cellular and molec-
ular interaction network [3]. Correlation-based networks
have been frequently used to analyze gene expression data
[4,5], but these methods have not been widely applied
to the study of disease-related phenotypes. Barabási and
colleagues [6] used diagnostic coding data to assess phe-
notypic network relationships between different disease
categories, but not to analyze multiple quantitative phe-
notypes within one complex disease. Using COPD as an
example, we describe the application of network inference
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methods to explore the relationships between disease-
related phenotypes that have been found to be relevant
in determining disease severity and outcome, and, ulti-
mately,tobegintodefinethecomplexheterogeneityofthe
disease.
Methods
Network inference and comparison
To infer phenotypic networks, we used the Gaussian
graphical model (GGM) introduced by [7] and [8]. Briefly,
the model, which is based on the assumption that the vari-
ables have Gaussian distributions, infers the connection
between each pair of variables and creates a phenotypic
network based on partial correlations.
Assume that we have P phenotype variables and K sub-
jects. We begin by constructing a P × K matrix, Y,w h e r e
we assume that the elements of Y follow a multivariate
normal distribution:
Yi = (y1i,....yPi)T ∼ NP (μY, Y), i = 1,....K,
Here, yji represents the jth phenotype variable in the
ith subject, μ is the mean vector and   is the covariance
matrix. The covariance matrix  Y and the partial correla-
tion matrix (denoted by  )f o rY are estimated (see [9]).
The partial correlation (PCOR) ωjk measures the corre-
lation between variable j and variable k while controlling
for all other variables. Therefore, ωjk representsthecondi-
tional dependency between variable j and variable k,w i t h
ωjk = 0 if the two variables are independent conditional
on all other variables and ωjk  = 0 if they are conditionally
correlated. For each pair of variables that are conditionally
dependent, the presumed causal relationship between the
variables is a direct one and independent of all other vari-
ables. We assume that these partial correlations represent
thehiddenconnectionsbetweenphenotypicvariablesthat
m a yh e l pt or e f i n ed i s e a s es u b t y p e s .
Under the null hypothesis in which all variables are
independent, Hotelling [10] gives the null distribution of
sample partial correlation ω as
p(ω|κ)=

1 − ω2(κ−3)/2  (κ/2)
π1/2  [(κ − 1)/2]
,
where κ is the degrees of freedom (K − P + 1).T h e r e -
fore,wecancomputethep-valuesfortheestimatedpartial
correlation coefficients for each pair of phenotypic vari-
ables and test for the presence of a significant connection
between those variables in the phenotypic network. In
addition, we can also test for differences in the network
connectivity between two groups of subjects by permuta-
tion tests. For example, to test for differential connectivity
between COPD cases and controls, we randomly swap
the labels of cases and controls and calculate the PCORs
in the shuffled groups, repeated 10,000 times, to obtain
the distribution of PCORs under the null hypothesis in
which the presence or absence of connections is not asso-
ciatedwiththecase-controlstatus.Theempiricalp-values
are reported. Analogously, we have also tested differential
connectivity between different genotypes for two previ-
ously identified genome-wide significant SNPs associated
with COPD using the same approach.
Opgen-Rhein and Strimmer [11] have extended the
GGM method to infer the directionality of the edges
between each pair of variables. They proposed a test of
directionality based on the log-ratios of standardized par-
tial variances. This method enables identification of a
“partially directed graph” where some of the significant
edges identified by GGM methods will have directions,
which might imply causality, while other edges remain
undirected.
Study populations and phenotypic variable selection
COPD is a disease defined by abnormal physiology, with
chronic airflow obstruction as the common, key fea-
ture [12]. Chronic airflow obstruction is characterized by
reductions in the forced expiratory volume in one second
(FEV1) and in the ratio of the FEV1 to the forced vital
capacity(FVC),whichareassessedbyspirometry.Clinical
epidemiological studies have identified multiple factors
that contribute to COPD, including cigarette smoking
(often quantified as pack-years, where an average of one
packofcigarettessmokedperdayforoneyearisonepack-
year) and increasing age. In addition, a variety of disease-
related phenotypes have been studied related to imaging,
exercise capacity, respiratory symptoms, and physiology.
Computerized tomography (CT) imaging enables assess-
ment of the severity and distribution of emphysema–the
destruction of lung parenchyma–as well as thickening of
airways [13-15]. The underlying assumption in our analy-
sis is that these phenotypic variables are not independent,
but, rather, interact to define distinct groups of patients
(subtypes). By defining these subtypes, we might better be
able to classify patients, understand their unique disease
characteristics, and ultimately direct them to appropriate
therapies.
The COPDGene Study [16] is a multi-center genetic
and epidemiologic investigation to study COPD and
other smoking-related lung diseases. In this study, 10,192
smokers (including 6,784 non-Hispanic Whites (NHW)
and 3,408 African-Americans (AA)) have completed a
detailed protocol, including questionnaires, pre-and post-
bronchodilator spirometry, high-resolution CT scanning
of the chest, exercise capacity (assessed by six minute
walk distance), and blood samples for genotyping. Sam-
ples were genotyped using the Illumina OmniExpress
platform, which assayed genetic polymorphisms at over
700,000 sites along the genome; the genotype data have
gone through standard quality-control procedures for
genome-wide association analysis. Briefly, a total of 221Chu etal. BMCSystemsBiology 2014, 8:78 Page 3 of 12
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subjects and 83,423 markers were excluded for qual-
ity control reasons, including identity-by-descent, gen-
der mismatches, genotype missingness, Hardy-Weinberg
disequilibrium in controls, and low minor allele fre-
quency. The details of the quality control procedures are
available at http://www.copdgene.org/sites/default/files/
GWAS_QC_Methodology_20121115.pdf.
For phenotypic network analysis, we selected 10 key
quantitative COPD-related phenotypes based on clini-
cal experts’ opinions (co-authors EKS, CPH, and MHC).
The phenotypes were chosen to represent major disease-
related components, including imaging, physiology, exer-
cise capacity, and exacerbations, as well as important
demographic variables (Table 1). Although over 300 vari-
ables were captured by questionnaires, clinical assess-
ments, and CT scanning in COPDGene, we chose
phenotypes to avoid duplicate assessment of the same
aspect of the disease (e.g., lung function, emphysema
severity, and airway wall thickness). For example, we
included FEV1 but excluded FEV1/FVC, as they are both
lung function phenotypes which assess airflow obstruc-
tion. Subjects with missing data in any of the 10 quan-
titative variables were excluded. Therefore, a complete
set of 8,141 subjects were used in the following analyses,
including 5,478 NHWs and 2,514 AAs. Case subjects were
defined by FEV1 < 80% predicted and FEV1/FVC < 0.7,
while control subjects were defined by FEV1 ≥ 80% pre-
dicted and FEV1/FVC ≥ 0.7. In addition to assessment
based on case-control status, we compared groups of sub-
jects homozygous for risk- and non-risk alleles at known
Table 1 Description of phenotypic variables
Variables
(abbreviation)
Descriptions/Comments
FEV1 (% predicted FEV1) Observed FEV1 (liters)/predicted FEV1 (liters),
with predicted valued from Hankinson refer-
ence equations
Emphysema (Emph) % Emphysema at -950 Hounsfield units(HU)
EmphysemaDistribution
(EmphDist)
Log ratio of emphysema at -950 HU in the
upper 1/3 of lung fields compared to the
lower 1/3 of lung fields
Gas Trapping (GasTrap) Airtrappingat-856HUonexpiratorychestCT
scan
Airway Wall Area (Pi10) Square root of the wall area of a hypothetical
10 mm internal perimeter airway
Exacerbation frequency
(ExacerFreq)
Number of COPD exacerbations during the
year before study enrollment
Six minute walk distance
(6MWD)
Measure of exercise capacity
BMI Body Mass Index
Age In years
Pack-Years (PackYear) One pack-year is defined as smoking one
pack (20 cigarettes) per day for one year
GWASSNPs,excludingheterozygotesfromthegenotype-
stratified phenotypic networks to maximize phenotypic
effects. To assess the impact of including phenotypic
variables that are not closely related to COPD on our
phenotypic networks, we also created networks including
heart rate and systolic blood pressure as well as networks
including two randomly generated variables.
Evaluation of COPD Longitudinally to Identify Predictive
Surrogate Endpoints (ECLIPSE, [17]) is a large longitu-
dinal study of COPD patients and controls with compre-
hensive phenotyping similar to COPDGene. Therefore,
we used a subset of 1,705 COPD cases (including 1,667
white subjects) with complete data for the 10 quantitative
variables at their baseline study visit to build pheno-
typic networks. All variables in Table 1 were available in
ECLIPSE, except for Emphysema Distribution and Gas
Trapping. Therefore, networks with 8 variables were built
for both COPDGene and ECLIPSE for comparison.
Results
Whole population phenotypic network in COPDGene
The ten selected COPD-related phenotypes in COPDGene
werefoundtobehighlyconnectedinthewholestudypop-
ulation. Out of 45 pairs of phenotypes, 37 had significant
PCORs with p-values< 0.05, and 29 pairs were significant
with p-values< 0.001 (density = 64.44%, where the den-
sity of a network is defined by the portion of all possible
connections in a network that are actual connections, see
Figure 1 and Table 2). The most highly connected nodes
were FEV1 and Gas Trapping (see Figure 1), with Gas
Trapping significantly connected with all of the analyzed
phenotypes.Inaddition,the16pairsthatwerenotdirectly
connected (p-values > 0.001) were connected through
only one transitive node based on shortest path analysis
[18]. The majority of shortest paths connected through
gas trapping (9 out of 16), suggesting that gas trapping is
a “hub” in the phenotypic network. This finding is con-
sistent with the high correlation observed between CT
gas trapping and spirometric measures [19], and also with
the observation that CT gas trapping encompasses the
two major pathological processes in COPD–emphysema
and small airway disease. Most edges in this whole pop-
ulation network remained statistically significant after we
stratified by race, while the NHW network edges were
slightlymoresignificantthantheAAnetworklikelydueto
larger sample size and better power. FEV1 and Gas Trap-
ping remained highly connected in the race-stratified net-
works. The top four pairs (CT Emphysema/Gas Trapping,
FEV1/Gas Trapping, FEV1/Pi10, and Gas Trapping/Age)
all stayed consistently top-ranked for the whole popu-
lation and race-stratified networks and were all highly
significant (see Table 2).
Since the ten variables were chosen based on their asso-
ciation with COPD, it was not surprising to find thatChu etal. BMCSystemsBiology 2014, 8:78 Page 4 of 12
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Whole Population Network, p<0.001
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PackYear
Figure 1 Whole population network (N=8,141). Undirected edges denote partial correlation coefficients that were significant at p < 0.001.
most of the variables were highly connected. To assess
the effects of variable selection, we repeated the analy-
sis with two scenarios: (1) we added two extra variables
randomly generated from a standard Gaussian distribu-
tion; and (2) we added two “extraneous” variables that
were presumably less closely related to COPD: systolic
blood pressure (SysBP) and heart rate (HR). As expected,
the Gaussian random variables were not connected to
any other variables. However, when the two “extraneous”
clinical variables were introduced they were found to be
connected to some of the other variables, but they were
notanin t egralpartoft hegra ph.T henetwor kwassparser ,
as there were fewer edges between these presumably less
related variables and other network components. Using
t h es a m et h r e s h o l d( p < 0.001), 37 pairs of variables were
significantly connected (density = 56.06%), including all
29 pairs that were significantly connected in the origi-
nal network analysis. The extra 8 edges resulting from
the two presumably unrelated variables included some
clinically expected pairs including demographic variables,
such as SysBP/BMI, SysBP/Age, and HR/Age. There were
also a few connections between HR and COPD pheno-
types which could be of potential interest (See Additional
file 1: Figure S1). Therefore, variables selection does play
an important role in the degree in which the variables are
connected.
Although our primary phenotypic network analysis was
based on undirected edges, we also created a pheno-
typic network using directed edges–where they could be
defined with certainty. The partially directed network
analysis showed that for 9 out of the 29 edges direc-
tionality could be established, with 7 variables directed
toward Gas Trapping (except for FEV1 and Emphysema,
See Figure 2).
Case-control phenotypic network comparison in
COPDGene
We then built phenotypic networks for COPD case and
control groups separately to examine the similarities and
differences in phenotypic relationships between these
two groups. Separate GGM networks were estimated in
COPDGene for smoking controls with normal spirome-
try (n = 3597) and COPD cases with moderate to very
severe airflow obstruction (GOLD Stage ≥ 2,n = 2894)
to explore the impact of COPD on phenotypic relation-
ships. Using p-value = 0.05 as the threshold for statistical
significance, the case and control networks each had 30
significant edges. The top pairs of variables were con-
sistent in these two phenotypic networks, including CT
Emphysema/GasTrapping, GasTrapping/BMI, GasTrap-
ping/Age, and CT Emphysema/Pi10, with a total of 17
edges present in both subgroups. However, the presenceChu etal. BMCSystemsBiology 2014, 8:78 Page 5 of 12
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Table 2 Edges of whole population network with p-values < 0.001
Node 1 Node 2
Whole population NHW AA
P-value PCOR P-value PCOR P-value PCOR
Emphysema Gas Trapping <E-238 0.654 <E-223 0.675 2.94E-239 0.594
FEV1% pred Gas Trapping 1.88E-238 -0.353 5.59E-223 -0.411 5.64E-64 -0.328
FEV1% pred Airway Wall Area 4.83E-193 -0.320 8.54E-138 -0.328 2.09E-38 -0.254
Gas Trapping Age 2.04E-102 0.234 7.49E-92 0.269 1.36E-26 -0.210
Gas Trapping BMI 7.47E-97 -0.228 1.07E-61 -0.221 2.13E-23 -0.197
6MWD BMI 7.35E-73 -0.198 5.37E-56 -0.210 2.13E-23 0.197
Airway Wall Area 6MWD 5.29E-64 -0.185 4.66E-32 -0.158 4.78E-19 0.176
Age Pack-years 7.47E-63 0.183 1.51E-23 0.134 1.75E-12 0.140
FEV1% pred 6MWD 6.49E-60 0.179 1.47E-76 0.246 4.05E-26 -0.208
FEV1% pred Exacerbation Frequency 2.66E-37 -0.140 1.13E-23 -0.135 1.32E-08 -0.113
FEV1% pred Emphysema 4.00E-37 -0.140 1.17E-09 -0.082 7.86E-06 -0.089
Emphysema Airway Wall Area 9.27E-33 -0.131 1.16E-27 -0.146 2.85E-13 0.145
FEV1% pred BMI 2.22E-25 -0.115 2.03E-17 -0.114 1.03E-06 -0.097
FEV1% pred Pack-years 4.86E-24 -0.111 1.46E-20 -0.125 5.74E-06 0.090
6MWD Pack-years 1.78E-16 -0.091 8.24E-23 -0.132 2.07E-07 -0.103
Gas Trapping 6MWD 7.75E-12 -0.075 0.2569 -0.015 0.3793 -0.017
Exacerbation Frequency 6MWD 2.07E-11 -0.074 9.03E-12 -0.092 0.00015 -0.075
Airway Wall Area Age 7.17E-10 -0.068 0.3368 -0.012 0.5379 -0.012
Emphysema Emphysema distribution 6.35E-07 0.0551 2.77E-05 0.056 0.005 0.055
Emphysema distribution Gas Trapping 9.39E-07 -0.0543 0.0001 -0.051 4.55E-05 -0.081
BMI Age 6.32E-06 0.0500 0.0061 0.037 0.1127 0.031
Gas Trapping Exacerbation Frequency 9.07E-06 0.0491 0.0095 0.035 0.1506 -0.028
Emphysema distribution BMI 1.19E-05 -0.0485 0.0493 -0.026 1.25E-05 -0.087
Emphysema BMI 1.90E-05 -0.0473 5.06E-05 -0.054 4.55E-05 0.081
Gas Trapping Airway Wall Area 2.86E-05 -0.0463 0.0121 -0.033 0.2662 0.022
Airway Wall Area Exacerbation Frequency 5.50E-05 0.0447 8.66E-05 0.053 0.004 0.057
Gas Trapping Pack-years 0.00011 0.0426 0.0002 0.049 0.027 0.044
Emphysema distribution 6MWD 0.00015 -0.0418 0.0006 -0.045 0.0015 -0.063
Exacerbation Frequency BMI 0.00023 0.0407 0.1588 0.019 0.0908 -0.033
of these edges in both groups does not exclude the pos-
sibility that these partial correlations could be associated
with case-control status. The permutation tests showed
some additional differences between the networks, where
24 pairs with significantly different p-values in the com-
parisonbetweencaseandcontrolnetworkswereobserved
(See Additional file 2: Table S1). For example, the Gas-
Trapping/BMI pair had significant negative connections
in both groups, but was more strongly connected in
the case group than the control group. There were 32
pairs significantly associated with case-control status (See
Figure 3). While most pairs had very similar patterns
of correlation in both groups, one of the notable excep-
tions was between CT Emphysema and BMI. Higher CT
emphysemawasassociatedwithhigherBMIinthecontrol
g r o u pb u tw a sa s s o c i a t e dw i t hl o w e rB M Ii nt h ec a s e
group, and both associations were statistically significant.
Moderate/Severe COPD network comparison in COPDGene
Next,weconstructedphenotypicnetworksinCOPDGene
moderate COPD cases (GOLD= 2,n = 1563) and severe
to very severe COPD cases (GOLD ≥ 3,n = 1331)
to test for association between the phenotypic networks
and disease severity. The moderate COPD network had
25 edges under the p-value < 0.05 threshold, while the
severe COPD network had 24–slightly fewer connec-
tions than the case-control networks in the section above,
likely due to smaller sample size (See Additional file 2:
Table S1). Globally, the differences between the two net-
works of COPD cases were less pronounced than theChu etal. BMCSystemsBiology 2014, 8:78 Page 6 of 12
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Whole Population Network, directed
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Figure 2 Partially directed network from the whole COPDGene population (N=8,141). The topology of the network is identical to the
correlation graph in Figure 1, but the edges with significant directionality are oriented.
case-control network comparison, with only 17 pairs with
significant differential connections according to the per-
mutation testing (Figure 4). However, when we compared
thesmokingcontrolswiththemoderateandsevereCOPD
case groups separately, we observed many pronounced
differences in the control/severe COPD comparison, with
multiple pairs significantly positively correlated in one
network and negatively correlated in another. In many
cases, we find the control group and severe COPD group
at the opposite ends of the distribution, with the moderate
COPD group in the middle. For example, CT Emphy-
sema/6MWD had a negative correlation in the severe
COPD network, no correlation in the moderate COPD
group, and a strongly positive correlation in the control
group. We also found that CT Emphysema and BMI were
positively correlated in the control group, not correlated
in the moderate COPD group, and negatively correlated
in the severe COPD group. Figure 5 shows the BMI-CT
Emphysemapartialresidualplot(the residuals of BMI and
CT Emphysema from regressing out the other 8 variables)
in the three groups, and we can see that the negative asso-
ciation between BMI and emphysema was only present in
severe COPD cases. Table 3 shows the partial correlation
coefficients and Pearson correlation coefficients between
BMI and emphysema, and we observe that the opposite
relationships between the control and COPD groups only
became apparent after we regressed out the other 8 vari-
ables in the partial correlation framework. These results
suggest that partial correlations could provide additional
insight about the relationships between these phenotypes
beyond standard epidemiological analyses.
Genetic-based network comparison in COPDGene
WealsoconstructedphenotypicnetworksforCOPDGene
subjects defined by their genotypes at two SNPs pre-
viously associated with COPD in genome-wide associ-
ation studies: rs1980057 (HHIP) [20,21] and rs7671167
(FAM13A)[22].Separatenetworkswerebuiltforhomozy-
gous samples (2 copies of the COPD-risk allele or 2 copies
of the non-risk allele) for each of these SNPs. Note that
in both loci, the minor allele has been associated with
COPD protection. We only built genotype-stratified phe-
notypicnetworksforNHWsubjects,asthisFAM13ASNP
did not have a significant association with COPD in the
AA population in previous GWAS [23], and the HHIP
SNP was a relatively uncommon variant in AA population
(MAF=0.10) with few homozygous minor allele subjects.
Using permutation tests, we observed that only a
few phenotype pairs significantly differed between these
genotype-stratified phenotypic networks, and none of the
edges was significant in opposite directions (See Figure 6
and Additional file 3: Table S2, Additional file 4: Table S3).Chu etal. BMCSystemsBiology 2014, 8:78 Page 7 of 12
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Figure 3 Comparison of COPDGene case and control networks. Undirected edges represent significantly different partial correlation
coefficients between case and control subjects. The green edges are present in both groups (p < 0.05) and the correlations are in the same
direction of effect. The red edges are present in both groups but the correlations are in the opposite direction of effect. The black edges are present
in one group but not the other.
The most discordant phenotype pair for FAM13A was
FEV1/Emphysema, which was negatively correlated in the
FAM13A COPD-non-risk group but not correlated in
the FAM13A COPD-risk group. Other pairs that showed
differential connection between the two groups include
Pi10/Exacerbation Frequency and Age/CT Emphysema.
For HHIP, we found FEV1/Exacerbation Frequency to
be negatively correlated in both homozygous groups,
but the partial correlation was significantly stronger in
the COPD-non-risk group than in the COPD-risk group
(−0.21 vs. −0.13). There were a few other pairs with only
one homozygous group deviating from the null distribu-
tion(p-values< 0.05)basedonthepermutationtests,and
the signal was not as strong. Overall, the genetic variables
did not have effects on the phenotypic networks that were
as great as case-control status or COPD severity.
ECLIPSE network comparison
Finally, we constructed phenotypic networks from ECLIPSE,
another independent COPD population, and compared
the results between the ECLIPSE and COPDGene net-
works. The major difference between these two cohorts is
that ECLIPSE contains mostly moderate to severe COPD
samples (GOLD 2-4) and mostly Caucasians. Therefore,
we performed the comparative studies on two sets of
sub-populations: (1) All COPD cases (GOLD 2-4, n=2,894
for COPDGene and n=1,705 for ECLIPSE); (2) NHW
COPD cases only (n=2,264 for COPDGene and n=1,667
for ECLIPSE). Only 8 out of 10 variables in Table 1 were
available in ECLIPSE, therefore the networks were built
with 8 nodes and 28 possible edges. The results show that
the networks from two populations were very similar (see
Additional file 5: Table S4, Additional file 6: Table S5, and
Additional file 7: Figure S2.), with minor differences. In
all COPD cases, 15 pairs were significant with p<0.001
in COPDGene, out of which 12 were also significant in
ECLIPSE (all of them were in the same direction). In
white COPD cases, 16 pairs were significant with p<0.001
in COPDGene, out of which 13 were also significant in
ECLIPSE. The most striking difference is that Pi10/BMI
had the second highest correlation in ECLIPSE (in both
analyses), but it was not significant in COPDGene. Over-
all, the networks from these two populations are reason-
ably comparable, and most of the strongest connections
from COPDGene can be found in another independent
population.
Discussion
Complex diseases are assessed using an array of disease-
related phenotypic variables, which may have subtle, hiddenChu etal. BMCSystemsBiology 2014, 8:78 Page 8 of 12
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Moderate vs Severe COPD cases
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Figure 4 Comparison of moderate and severe COPD networks. Undirected edges represent significantly different partial correlation coefficients
between moderate and severe COPD subjects. The green edges are present in both groups (p < 0.05) and the correlations are in the same direction
of effect. The red edges are present in both groups but the correlations are in the opposite direction of effect. The black edges are present in one
group but not the other.
relationships that are not captured by standard epi-
demiological analyses. Understanding the relationships
between these disease-related phenotypes in large, well-
characterized study populations may provide insight into
disease heterogeneity. Different approaches have been
proposed to study the relationship between multiple phe-
notypes, including structural equation modeling [24] and
mutual information [25]. We have developed an approach
for constructing networks of phenotypic variables based
on partial correlations between quantitative, disease-
related phenotypes; for testing the statistical signifi-
cance of those partial correlations within one phenotypic
network; and for comparing those partial correlations
between phenotypic networks constructed using differ-
ent groups of subjects. The correlation-based networks
that we analyzed are highly connected and not scale-free,
as opposed to the sparse, scale-free networks that are
observed in many biological and physical phenomena [2].
This is not surprising, as we built the networks based on
a modest number of pre-selected variables closely related
to the complex disease of interest.
The correlation-based networks have enabled us
to detect novel relationships between disease-related
phenotypesthatwouldnothavebeenobservedinasingle-
variable analysis. Network based approaches are particu-
larly useful in the studies of COPD, which is a complex
disease with diverse clinical and molecular phenotypic
profiles that might represent different subtypes [26]. In
our study, the COPD network in the whole COPDGene
study population provided a variety of clinically intuitive
observations, such as the central location of gas trap-
ping in the network–which includes both of the major
COPD-related causes of airflow obstruction, emphysema
and small airway disease. This key role of gas trapping
was especially notable in the partially directed network
(Figure2).ComparisonsbetweenCOPDcasesandcontrol
subjects showed similar relationships for most variables,
but an intriguing switch in the direction of the relation-
ship between body mass index and CT emphysema was
observed in controls compared to cases. Cachexia can
accompany advanced COPD with severe emphysema, so
a negative relationship between BMI and emphysema in
COPD cases is clinically reasonable. Since the same radia-
tiondosewasusedinallCOPDGenesubjects,thepositive
relationship between BMI and emphysema in control sub-
jects could relate to the increased radiation noise withChu etal. BMCSystemsBiology 2014, 8:78 Page 9 of 12
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Figure 5 Partial residual plot. The partial residual plot between BMI and CT Emphysema for the smoking controls (black), moderate COPD cases
(green), and severe COPD cases (red) networks. The partial residuals are the residuals of BMI and CT Emphysema from regressing out the other 8
variables.
higherBMI,whichcouldflattenthedensityhistogramand
artifactually increase the estimated degree of emphysema
using densitometric thresholds.
Other phenotypic relationships are less intuitive but
may point to important biological pathways. Comparison
between moderate and severe/very severe COPD sub-
jects showed a variety of interesting correlations between
phenotypes.Forexample,increasedemphysemawasasso-
ciated with reduced exercise capacity (6MWD) in severe
COPD subjects but not in the moderate COPD group.
Exercise capacity, assessed by 6MWD, includes many
components but is likely significantly related to inspi-
ratory capacity. In severe disease, inspiratory capacity
is limited by baseline hyperinflation, which is observed
by emphysema on CT scan. However, in moderate dis-
ease, other parameters are major determinants of 6MWD.
Inspiratory capacity may be limiting with dynamic hyper-
inflation in moderate COPD subjects, but inspiratory
capacity will likely not be closely associated with emphy-
sema in this subgroup. It is unclear why airway wall area
(Pi10) was significantly correlated with body mass index
(BMI) in one of our study populations (ECLIPSE) but
not the other (COPDGene). One possible explanation is
that the CT radiation dose for ECLIPSE was substantially
lower than in COPDGene, and this difference in radiation
dose could have impacted how BMI influenced airway
wall measurements.
Phenotypic networks have previously been stud-
ied in the context of multi-dimensional analyses that
have included both phenotypic and genetic information
[27,28]. Our method can also be applied in such inte-
grative analyses. In particular, we examined the effects
of genetic perturbations on the relationships between the
phenotypes. In our COPD example, relatively few phe-
notypic interactions were different between homozygotes
for alternative alleles of COPD GWAS regions near HHIP
and FAM13A. Given the modest effects of these vari-
ants, and most other complex disease GWAS regions,
these results are not surprising. However, the observed
differences, such as the FEV1-emphysema relationship in
alternate FAM13A genotypes, could provide clues regard-
ing the underlying mechanisms by which these GWAS
regions influence disease susceptibility. These results sug-
gest that FAM13A may lead to reduced FEV1 through
mechanisms other than increased emphysema, which is
Table 3 Partial correlation and Pearson correlation
coefficients for BMI and CT emphysema
Control Moderate COPD Severe COPD
Partial correlation
coefficients
0.07 0.008 -0.07
Pearson correlation
coefficients
-0.07 -0.20 -0.46Chu etal. BMCSystemsBiology 2014, 8:78 Page 10 of 12
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Figure 6 Comparison of genetically perturbed networks. (1) HHIP in non-Hispanic White (NHW) subjects (2 copies of the COPD-risk or non-risk
allele) and (2) FAM13A NHW (2 copies of the COPD-risk or non-risk allele). The green edges are present in both groups (p < 0.05) and the partial
correlations have the same sign, but the magnitude of effect is significantly different between genotype groups. The black edges are present in one
group but not the other.
a testable hypothesis for future research. Similarly, the
weaker relationship of FEV1 and exacerbation frequency
in the COPD-associated group could indicate that any
relationship of the HHIP locus to exacerbations may not
be mediated through reduced FEV1.
Although published studies have described methods for
assessing relationships between disease diagnostic cate-
gories in a network context [6,29], we instead focused on
multiple disease-related phenotypes within one complex
disease. While we believe this represents an important
new approach, several limitations of our work need to be
acknowledged. It is not clear whether it is preferable to
use a weighted network, in which all edges are present but
of variable magnitude, or an unweighted network, with
an admittedly somewhat arbitrary threshold for placing
an edge. Further work will also be required to determine
t h eo p t i m a la p p r o a c hf o ra s s e s s i n gt h ei m p a c to fg e n e t i c
factors on phenotypic networks. We have compared alter-
natehomozygousclasses,butthatapproacheliminatesthe
information in the typically larger heterozygous genotype
group.
Conclusion
In conclusion, we have presented a framework for ana-
lyzing and comparing partial correlations between multi-
ple, quantitative disease-related phenotypes in networks.
These phenotypic networks could provide insights into
disease susceptibility, disease severity, and genetic mech-
anisms. Future directions will involve refining the
approaches for selecting phenotypes to include in such
networks as well as improved approaches for incorporat-
ing genetic information. Ultimately, these phenotypic net-
works may prove useful in developing novel classification
systems for complex diseases.
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